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http://www.retrovirology.com/content/10/1/40RESEARCH Open AccessLKB1 tumor suppressor and salt-inducible kinases
negatively regulate human T-cell leukemia virus
type 1 transcription
Hei-Man Vincent Tang1, Wei-Wei Gao1, Ching-Ping Chan1, Yeung-Tung Siu1, Chi-Ming Wong1, Kin-Hang Kok1,
Yick-Pang Ching2, Hiroshi Takemori3 and Dong-Yan Jin1*Abstract
Background: Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL). Treatment options
are limited and prophylactic agents are not available. We have previously demonstrated an essential role for
CREB-regulating transcriptional coactivators (CRTCs) in HTLV-1 transcription.
Results: In this study we report on the negative regulatory role of LKB1 tumor suppressor and salt-inducible kinases
(SIKs) in the activation of HTLV-1 long terminal repeats (LTR) by the oncoprotein Tax. Activation of LKB1 and SIKs
effectively blunted Tax activity in a phosphorylation-dependent manner, whereas compromising these kinases, but
not AMP-dependent protein kinases, augmented Tax function. Activated LKB1 and SIKs associated with Tax and
suppressed Tax-induced LTR activation by counteracting CRTCs and CREB. Enforced expression of LKB1 or SIK1 in
cells transfected with HTLV-1 molecular clone pX1MT repressed proviral transcription. On the contrary, depletion of
LKB1 in pX1MT-transfected cells and in HTLV-1-transformed T cells boosted the expression of Tax. Treatment of
HTLV-1 transformed cells with metformin led to LKB1/SIK1 activation, reduction in Tax expression, and inhibition of
cell proliferation.
Conclusions: Our findings revealed a new function of LKB1 and SIKs as negative regulators of HTLV-1 transcription.
Pharmaceutical activation of LKB1 and SIKs might be considered as a new strategy in anti-HTLV-1 and anti-ATL
therapy.
Keywords: Adult T-cell leukemia, Human T-cell leukemia virus type 1, LKB1 tumor suppressor, Salt-inducible kinases,
Metformin, Tax oncoproteinBackground
HTLV-1 was the first human retrovirus shown to be the
etiological agent of adult T-cell leukemia (ATL). Over 20
million people are infected with HTLV-1 worldwide.
ATL is a highly aggressive and fatal malignancy of CD4+ T
lymphocytes that develops in 2-5% of carriers, usually
after more than 20 years of HTLV-1 latency [1,2]. Al-
though it is a slow and multifactorial process, progression
of ATL tightly correlates with high HTLV-1 proviral load
[3]. Treatments for ATL are unspecific and unsatisfactory.
Once developed, ATL is minimally treatable. In addition,* Correspondence: dyjin@hku.hk
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reproduction in any medium, provided the orprophylactic agents that can prevent the development of
ATL in carriers of HTLV-1 remain to be identified [2].
Expression of HTLV-1 provirus is transcriptionally
mediated through the viral transactivator Tax, which po-
tently stimulates the activity of long terminal repeats
(LTR) by activating the cellular transcription factor CREB
and coactivators such as CREB-binding protein (CBP) and
CREB-regulating transcriptional coactivators (CRTCs), also
known as transducers of regulated CREB activity (TORCs)
[4-9]. We have previously characterized the essential roles
of Tax, CREB and CRTCs in this process [7,10,11]. Particu-
larly, we have demonstrated the requirement of CRTCs in
Tax activation of the LTR [7].
In addition to a viral LTR, a battery of cellular genes
can also be activated by Tax primarily through CREBd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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crucial role in the initiation of malignant transformation
[12]. Tax also cooperates with other viral oncoproteins such
as HBZ in later phases of leukemogenesis [13]. It has been
generally accepted that activation of both CREB and NF-κB
by Tax is required for full-blown transformation [12].
Consistent with Tax playing an essential role in both
viral transcription and oncogenesis, counteracting Tax
function or eliminating Tax-expressing cells has shown
anti-HTLV-1 and anti-ATL effects [14,15]. Thus, we hy-
pothesized that identification of protein kinases that
regulate Tax might reveal new strategies for disease pre-
vention and intervention using small-molecule agonists
and antagonists of such kinases. In searching for these
kinases, we noticed that CRTCs are regulated by up-
stream kinases such as LKB1, AMP-activated protein ki-
nases (AMPKs) and salt-inducible kinases (SIKs) [16-18].
LKB1 is a tumor suppressor inactivated in Peutz-Jeghers
syndrome, a rare autosomal dominant disorder charac-
terized by gastrointestinal polyps and a higher risk of
malignancy [19]. LKB1 phosphorylates and activates
AMPKs and AMPK-related kinases, which in turn phos-
phorylate CRTC2 at S171, leading to its association with
14-3-3 proteins and sequestration in the cytoplasm [16].
As such, AMPKs and SIKs are major kinases that regu-
late CRTCs [18,20]. However, the roles of LKB1, AMPKs
and SIKs in Tax-mediated transcriptional activation re-
main elusive.
In this study, we investigated the regulatory roles of
LKB1, AMPKs and SIKs in Tax activation of the HTLV-1
LTR. We demonstrated LKB1 and SIKs to be negative reg-
ulators of HTLV-1 transcription. Our work suggests a new
model in which LKB1 and SIKs suppress Tax-mediated
LTR activation by targeting CRTCs and CREB. Our find-
ings also implicate the utility of small-molecule agonists
of LKB1 and SIKs in anti-HTLV-1 and anti-ATL therapy.
Results
LKB1 inhibits Tax activation of LTR in a kinase-dependent
manner
Four lines of analysis prompted us to investigate the role
of LKB1 in HTLV-1 transcription. First, chromosomal
rearrangements at 19p13.3, where LKB1 is located, have
been reported in some ATL cells [21]. Second, it will be
of interest to see whether LKB1 is another repressor of
HTLV-1 replication like p53 and p30II, which play a role
in viral persistence and transformation [22,23]. Third,
small-molecule agonists of LKB1 have been extensively
tested as targeted therapeutics [19]. Finally, Tax-dependent
transcriptional activation is particularly robust in LKB1-
null HeLa cells.
To determine whether LKB1 might inhibit Tax activity,
we coexpressed LKB1 and Tax in HeLa cells (Figure 1A).
The expression of Tax was driven by a CMV promoterand the level of Tax protein remained unchanged when
the dose of LKB1 was escalated (Figure 1A, lane 3 com-
pared to 4–6). In the presence of Tax, LKB1 effectively
abolished LTR-driven luciferase reporter expression even
at the lowest dose (Figure 1B, lane 2 compared to 4–6).
Similar results were also obtained with LKB1-K48R
(Figure 1B, lanes 7–10), a dominant active mutant [24].
On the contrary, two kinase-dead mutants [25,26],
LKB1-D194A and LKB1-K78I, had no influence on Tax
activation of LTR (Figure 1B, lanes 11–14 and 15–18).
LKB1 negatively regulates CREB-mediated transcrip-
tion through AMPK- and SIK-dependent inhibitory
phosphorylation of CRTCs [27,28], which are also essen-
tial coactivators of Tax [7]. We therefore further asked
whether LKB1 might exert any effects on CRTC1
coactivation of Tax. When we coexpressed LKB1 and
CRTC1 in HeLa cells (Figure 1C inset), we found that
wild-type LKB1 (LKB1-WT), but not its kinase-defective
mutant LKB1-D194A, abrogated LTR activation either
by CRTC1 alone (Figure 1C, lanes 1–4 compared to 5–8
or 9–12) or by CRTC1 and Tax (Figure 1C, lanes 13–16
compared to 17–20 or 21–24). To verify the suppressive
effect of LKB1 on Tax in T lymphocytes, which are the
target cells of HTLV-1, we expressed LKB1 in Jurkat
cells. We observed less pronounced activation of LTR by
Tax in LKB1-proficient Jurkat cells compared to LKB1-
null HeLa cells (Figure 1B); however, introduction of
exogenous LKB1 resulted in further inhibition of Tax ac-
tivation of LTR (Figure 1D, lanes 1–4 compared to 5–8).
Hence, LKB1 suppresses Tax- and CRTC-mediated acti-
vation of HTLV-1 LTR in a kinase-dependent manner.
SIKs inhibit Tax activation of LTR in a kinase-dependent
manner
The role of AMPKs in phosphorylation and activation of
CRTCs has been documented in worms and humans
[28,29]. In addition, SIKs [30], which were identified in
the adrenal glands of rats fed with high salt diet and are
also phosphorylated by LKB1, are alternative upstream
regulators of CRTCs in CREB signaling [31]. With this
in mind, we sought to determine the role of AMPKs and
SIKs in Tax activation of LTR.
When we expressed EGFP-AMPKα2-WT and its consti-
tutively active mutant (T172D) in HeLa cells, Tax-mediated
activation of LTR was unaffected (Figure 2A, lanes 4 com-
pared to 5 and 6; and lane 10 compared to 11 and 12). The
expression and activity of EGFP-AMPKα2 proteins in HeLa
cells were verified by immunoblotting. Detection of phos-
phorylated ACC, a known substrate of AMPK, indicated
that the EGFP-AMPKα2 proteins expressed are catalytically
active (Figure 2A, right panel, lanes 10 compared to 5, 6, 11
and 12). Because AMPKα2 is highly representative of the
AMPK family [19], these results suggested that AMPK is
unlikely involved in Tax activation of LTR.
Figure 1 LKB1 suppresses Tax-mediated LTR activation in a kinase-dependent manner. (A) Expression of LKB1 and Tax. HeLa cells were
transfected with pIEX, pCMV-Tag2-LKB1, or pIEX plus escalating amounts of pCMV-Tag2-LKB1. Cell lysates were probed with mouse anti-Tax,
mouse anti-Flag and mouse anti-α-tubulin (α-tub). (B) Kinase activity of LKB1 is required for suppression of Tax activity. HeLa cells were transfected
with pLTR-Luc (100 ng), a fixed amount of pIEX (100 ng) and escalating amounts of LKB1 plasmids (25, 50 and 100 ng). Protein expression was analyzed
(inset). Fold activation is calculated from pLTR-Luc activity normalized to that of pSV-RLuc. Results of this dual luciferase assay represent means from three
independent experiments and error bars indicate SD. The differences between groups 2 and 6, and between groups 2 and 10 are statistically significant
by two tailed Student’s t test (p = 0.00020 for both). In contrast, there is no statistically significant difference between groups 2 and 14 (p = 0.34) or
between groups 2 and 18 (p = 0.29). (C) Kinase-dependent suppression of CRTC1 and Tax by LKB1. HeLa cells were transfected with pLTR-Luc (100 ng),
a fixed amount of pIEX (100 ng) plus pCMV-Tag2-LKB1 (WT or D194A) (30 ng), and escalating amounts of expression plasmids (18, 37 and 75 ng) for
CRTC1. Statistically significant differences are found between groups 4 and 8 (p = 0.00097) and between groups 16 and 20 (p = 0.000035). (D) LKB1
inhibition of LTR in T cells. Jurkat cells were transfected with pLTR-Luc (300 ng), a fixed amount of pCAG-Tax-V5 (200 ng) and escalating amounts of LKB1
plasmid (50, 100 and 200 ng). The difference between group 5 and groups 6–8 is statistically significant (p = 0.00084).
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SIK1-WTand its constitutively active (T182D) and kinase-
defective (K56M) mutants were found to be expressed to
comparable levels in HeLa cells (Figure 2B inset). The
SIK1-T182D mutant was used to mimic the activation of
SIK1 by LKB1 and was therefore expected to be more ac-
tive than SIK1-WT [27,32]. Indeed, SIK1-T182D com-
pletely suppressed Tax activation of LTR (Figure 2B, lane
13 compared to 19–21), while SIK1-WT displayed only
moderate suppressive effect (Figure 2B, lane 13 compared
to 16–18). In contrast, SIK1-K56M even augmented Tax
activity at the highest dose (Figure 2B, lane 13 compared
to 22–24).
We further extended our analysis to SIK2 and SIK3. The
respective constitutively active (SIK2-T175D and SIK3-T163D) and kinase-defective mutants (SIK2-K49M and
SIK3-K37M) were expressed in HeLa cells (Figure 2C, right
panel) [27,33]. It is noteworthy that SIK3-WT as well as
constitutively active phosphomimetic mutants of SIK2 and
SIK3 exhibited strong suppressive effects on Tax activity
(Figure 2C, lane 8 compared to 10, 12 and 13). Since SIK2-
WT did not inhibit Tax activity (Figure 2C, lane 9), the use
of SIK1-T175D to mimic the activation by LKB1 was neces-
sary. No alteration in Tax activation of LTR was observed
for SIK2/3 kinase-defective mutants (Figure 2C, lane 8
compared to 11 and 14). These results were generally con-
sistent with the notion that LKB1 phosphorylates and acti-
vates SIKs, which in turn phosphorylate and inhibit CRTCs.
To verify this model, we asked whether SIK1-T182D
might counteract CRTC coactivation of Tax. Indeed,
Figure 2 SIKs suppress Tax-mediated LTR activation in a
kinase-dependent manner. (A) Influence of AMPK. HeLa cells were
transfected with pLTR-Luc (100 ng), a fixed amount of pIEX (100 ng)
and escalating amounts of AMPK plasmids (25, 50 and
100 ng). Endogenous p-ACC indicates AMPK activity. Two tailed
Student's t test was performed (groups 4 and 6: p = 0.16; groups 10
and 12: p = 0.30). (B) Kinase activity of SIK1 is required for
suppression. HeLa cells were transfected with pLTR-Luc (100 ng), a
fixed amount of pIEX (100 ng) plus pCMV-Tag2-LKB1-WT/D194A
(30 ng), and escalating amounts of SIK1 plasmids (25, 50 and 100
ng). p values were calculated for selected groups (13 and 18:
0.00038; 13 and 21: 0.0000030; 13 and 24: 0.000050). (C) Kinase
activity of SIK2/3 is required for suppression. HeLa cells were
transfected with pLTR-Luc (100 ng), a fixed amount of pIEX (100 ng)
and pCMV-Tag2-SIK2-WT/T175D/K49M (30 ng) or pCMV-Tag2-SIK3-
WT/T163D/K37M (30 ng). p values were calculated for selected
groups (8 and 10: 0.0050: 8 and 12: 0.010; 8 and 13: 0.00030; 8 and
11: 0.25; 8 and 14: 0.37). (D) Suppression of CRTC1- and Tax-
mediated LTR activation by activated SIK1. HeLa cells were
transfected with pLTR-Luc (100 ng) and a fixed amount of pIEX
(100 ng) and pcDNA3.1/V5-CRTC1 (18 ng) or pCMV-Tag2-SIK1-T182D
(50 ng). The difference between groups 4 and 8 is statistically
significant (p = 0.000054). (E) Cooperation of activated SIK1/2/3. A
fixed amount of pIEX (100 ng) and a fixed total amount (30 ng) of
pCMV-Tag2-LKB1-WT, pCMV-Tag2-SIK1-T182D, pCMV-Tag2-SIK2-T175D,
pCMV-Tag2-SIK3-T163D or their indicated combinations were
transfected into HeLa cells. p values were calculated for selected
groups (4 and 7: 0.0066; 4 and 8: 0.00046; 7 and 10: 0.00016; 8 and
10: 0.00017).
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ity of CRTC1 and Tax (Figure 2D, lanes 2–4 compared
to 6–8), implicating SIKs as the potential targets of
LKB1 in the activation of LTR by CRTCs and Tax. Fur-
thermore, we coexpressed three active SIKs in HeLa
cells. Interestingly, the inhibition of Tax activity was
more robust when SIK1 + SIK2, SIK1 + SIK3 or SIK1 +
SIK2 + SIK3 were expressed (Figure 2E, lanes 7, 8 and 10
compared to 4–6 and 9), suggesting that SIK1 might co-
operate with SIK2 and SIK3 to suppress Tax activity sub-
sequent to their activation by LKB1.
Depletion of LKB1 or SIKs augments Tax activation of LTR
Above we have shown that the kinase-dead mutants of
LKB1 and SIKs either have no influence on, or they en-
hance Tax activation of LTR in the LKB1-null HeLa
cells. Our results implied that loss of LKB1 or SIK ac-
tivity could de-repress the inhibition of Tax activity.
Complementary to these gain-of-function analyses,
here we further investigated the physiological import-
ance of LKB1 and SIKs in Tax activation of LTR by
compromising LKB1 and SIKs in HEK293T cells with
RNAi.
LKB1 was abundantly expressed in HEK293T cells and
the two independent siRNAs directed against LKB1
(siLKB1-1 and siLKB1-2) efficiently depleted its mRNA
and protein expression (Figure 3A, lane 1 compared to
2 and 3). Correspondingly, Tax-mediated LTR activation
was substantially potentiated in LKB1-depleted cells
(Figure 3B, lane 4 compared to 5 and 6). Likewise, the
effectiveness of two independent siRNAs targeting each
of the SIKs in depleting their corresponding mRNA was
validated (Figure 3C) and the potentiation of Tax activity
was also observed in individual SIK-compromised cells
(Figure 3D, lane 8 compared to 9–14). Thus, endoge-
nous LKB1 and SIKs are physiological repressors of Tax
function.
Association of Tax with LKB1 and SIKs
For LKB1 and SIKs to exert their influence on Tax, they
should form a protein complex with Tax inside the cell.
To test this, we performed coimmunoprecipitation as-
says in HEK293T cells.
A protein complex of Tax and LKB1 was detected in
cells expressing both entities (Figure 4A, lane 3). This asso-
ciation between Tax and LKB1 was specific, as complex for-
mation was not observed when either Tax or LKB1 alone
was expressed (Figure 4A, lanes 1 and 2). Interestingly, the
association between Tax and the kinase-dead LKB1-D194A
mutant was considerably less pronounced than that be-
tween Tax and LKB1-WT (Figure 4A, lane 6 compared
to 3). Thus, Tax might interact preferentially with active
LKB1. The catalytic activity of LKB1-WT in cells was vali-
dated by probing AMPKs phosphorylated at T172. An
Figure 3 Silencing of LKB1 and SIKs facilitates Tax activation of
LTR. (A) Verification of LKB1 knockdown. RT-qPCR was performed to
analyze LKB1 and GAPDH transcripts. Quantitation of mRNA
expression was achieved by comparative Ct method. Relative LKB1
mRNA expression in siGFP-transfected cells was taken as 1.
Endogenous LKB1 in siRNA-transfected HEK293T cells was also
analyzed by Western blotting at 72 hr post-transfection (inset). Two
independent LKB1-targeting siRNAs (siLKB1-1 and siLKB1-2) at a
concentration of 100 nM were used to deplete endogenous LKB1.
siGFP was used as a negative control. Statistically significant
differences exist between groups 1 and 2 or 1 and 3 (p = 0.0000033
or 0.0000073 by two tailed Student’s t test). (B) Downregulation of
endogenous LKB1 augmented Tax activation of LTR. After 36 hrs of
knockdown, plasmids pLTR-Luc, pSV-RLuc and pIEX were
cotransfected into HEK293T cells. The difference between groups 4
and 5 or 4 and 6 is statistically significant (p = 0.0045 or 0.0080).
(C) Verification of SIK knockdown by siRNAs. RT-qPCR was performed
as in A. p values for selected bars were calculated (1 and 4: 0.00020;
1 and 7: 0.00013; 2 and 11: 0.00027; 2 and 14: 0.00042; 3 and 18:
0.0000046; 3 and 21: 0.00012). (D) Downregulation of individual
endogenous SIK augmented Tax activity. Two independent siRNAs
at a concentration of 100 nM were used to deplete endogenous
SIKs in HEK293T cells. siGFP was used as a negative control. After
36 hrs of knockdown, plasmids pLTR-Luc, pSV-RLuc and pIEX were
cotransfected into cells. Cells were harvested 36 hrs after the second
transfection. Statistically significant differences exist between group
8 and each of groups 9–14 (p = 0.027, p = 0.001, p = 0.030, p = 0.0051,
p = 0.0034 and p = 0.037, respectively).
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ing LKB1-WT, but not LKB1-D194A (Figure 4A, lanes 2
and 3 compared to 5 and 6). Notably, expression of Tax
did not further enhance phosphorylation of AMPK by
LKB1 (Figure 4A, lane 3 compared to lane 2). Consistent
with this, an in vitro kinase assay with recombinant GST-
AMPK, LKB1 and Tax proteins indicated that the addition
of Tax did not significantly affect the kinase activity of
LKB1 on AMPK (Additional file 1: Figure S1, lanes 3–5
compared to lane 2). In addition to HEK293T cells, HTLV-
1-transformed T cells were also examined for the inter-
action between LKB1 and Tax. LKB1 was found in the pro-
tein complex precipitated with anti-Tax from MT2, MT4
and C8166 cells (Figure 4B, lanes 2–4 compared to 1). This
indicated an association of Tax with endogenous LKB1 in
these HTLV-1-transformed cells.
Likewise, a protein complex of Tax and SIK1 was also
observed in cells expressing Tax and SIK1-WT, but not in
cells expressing Tax and SIK-K56M, the kinase-dead mu-
tant (Figure 4C, lanes 2 and 4). Again, Tax seemingly pre-
ferred active over inactive SIK1. Additionally, Tax was also
found in a protein complex pulled down from cell lysates
with GST-SIK2 or GST-SIK3 protein bound to glutathione
beads (Figure 4D, lanes 2 and 3 compared to 1). Hence,
Tax preferentially associates with active LKB1 and SIKs.
LKB1 inhibition of Tax is mediated through SIKs, CRTCs
and CREB
Although we have shown that LKB1 and SIKs interacted
with Tax and inhibited its function, the order of events in
the signaling cascade remains to be characterized. Here,
we took advantage of various dominant inactive mutants
and siRNAs to dissect the LKB1-SIKs-CRTCs-CREB cas-
cade in Tax activation of LTR.
CRTCs and CREB are essential activators of the HTLV-1
LTR and they are regulated by LKB1 and SIKs (Figures 1C
and 2D) [7,27]. To formally address whether the suppres-
sive effect of LKB1 was mediated through CRTCs and
CREB, we examined whether and how GalCRTC1-M1 and
A-CREB might affect the potentiation of Tax activity in
LKB1-depleted cells.
GalCRTC1-M1 is a truncated mutant of CRTC1 fused to
a Gal4 DNA-binding domain and it displayed a potent
CRTC1-interfering activity [17]. A-CREB is a dominant in-
active form of CREB, which has been widely used [34].
Upon expression of GalCRTC1-M1 or A-CREB, the aug-
mentation of Tax activity ascribed to LKB1 depletion was
dampened or abrogated (Figure 5A). Although we cannot
exclude other possibilities, these results were generally con-
sistent with the notion that LKB1 requires intact CRTCs
and CREB to fulfill its negative regulatory role on Tax.
This result immediately raised a question as to whether
SIKs are the intermediate kinases that relay LKB1 signals to
CRTCs to regulate LTR activation by Tax. To address this,
Figure 4 Association of Tax with activated LKB1 and SIKs.
(A) Association with LKB1 in HEK293T cells. Cells were transfected with
expression plasmids pCMV-Tag2-LKB1 (WT/D194A) and pCAG-Tax-V5.
LKB1 was immunoprecipitated with anti-Flag. The precipitates were
analyzed by Western blotting with anti-Flag and anti-Tax, respectively.
The input lysates were also immunoblotted for LKB1, Tax and α-
tubulin. Detection of phospho-AMPK-T172 (p-AMPK-T172) and total
AMPKα2 indicated the kinase activity of LKB1. (B) Association with
endogenous LKB1 in T cells. Jurkat, MT2, MT4 and C8166 cells were
lysed and immunoprecipitated with anti-Tax. The precipitates were
immunoblotted with anti-LKB1 and anti-Tax. A longer exposure (long
exp.) of the LKB1 blot is also presented. The input lysates were
analyzed for LKB1 and β-actin. (C) Association with SIK1. HEK293T cells
were transfected with expression plasmids pCMV-Tag2-SIK1 (WT/K56M)
and pCAG-Tax-V5. SIK1 was immunoprecipitated with anti-Flag. The
precipitates were analyzed by Western blotting with anti-Flag and
anti-Tax. The input lysates were also probed for SIK1, Tax and α-tubulin.
(D) Association with SIK2 and SIK3. HEK293T cells were transfected with
expression plasmids for pEBG vector (v), pEBG-SIK2 (2), pEBG-SIK3 (3)
and pCAG-Tax-V5. GST-SIK2/3 was pulled down by glutathione-
Sepharose 4B. The pull-down fraction was analyzed by Western
blotting with anti-GST and anti-Tax. The input lysates were also probed
for SIK2/3, Tax and α-tubulin.
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siRNAs (Figures 5B and 5C). Consistent with our earlier re-
sults, LKB1 effectively abolished Tax activation of LTR
(Figure 5D, lane 3 compared to 2). Depletion of SIK1, SIK2
or SIK3 individually rescued LKB1-dependent suppression
partially (Figure 5D, lane 3 compared to 5–10), whereasknockdown of AMPKα1 and AMPKα2 with one siRNA,
which targets a conserved region of both isoforms, did
not cause a significant change (Figure 5D, lanes 4 compared
to 3). Notably, when we depleted all three SIKs simultan-
eously, the LKB1-mediated suppression was completely re-
stored (Figure 5D, lane 11 compared to 2 and 3). In keeping
with our earlier results (Figure 2E), this further corrobo-
rates the notion that SIKs cooperate with each other to me-
diate the inhibitory effect of LKB1 on Tax activity.
CRTC2 is targeted by SIKs and phosphorylation of
CRTCs at conserved serine residues has been suggested
as a mechanism of that targeting [27,35]. Taking advan-
tage of an unphosphorylatable CRTC1-S167A, we asked
whether the inhibitory activity of SIKs on LTR activation
might be mediated through CRTC1 phosphorylation at
S167. The experiment was done in the absence of Tax
since CRTC1-S167A is a constitutively active mutant
that mimics the effect of Tax. Consistent with previous
findings [6], CRTC1-WT exhibited modest basal activity
on LTR activation (Figure 5E, lane 1 compared to 2–4),
whereas LTR activation by CRTC1-S167A was more
robust (Figure 5E, lane 13 compared to 14–16). In the
presence of dominant active SIK2-T175D or SIK3-T163D,
the CRTC1-induced LTR activity was completely blunted
(Figure 5E, lanes 5–8 and 9–12 compared to 1–4). In
contrast, substantial activation of LTR by CRTC1-S167A
was seen in the presence of SIK2-T175D or SIK3-T163D
(Figure 5E, lanes 18–20 and 22–24 compared to 14–16),
suggesting that SIKs might transmit their inhibitory sig-
nal partially through phosphorylation of CRTC1 at S167.
On the other hand, mild suppression of CRTC1-S167A
activity by SIK2-175D and SIK3-T163D implicated that
SIK2 and SIK3 could also regulate CRTC1 through an
S167 phosphorylation-independent mechanism. Neverthe-
less, our collective results suggested that LKB1 operates
through SIKs, CRTCs and CREB to effect its suppression
on Tax activity.
LKB1 and SIK1 suppress proviral transcription in
HTLV-1-infected cells
Above we have characterized the role of LKB1 and SIKs
in suppressing Tax activity in LKB1-deficient HeLa cells
and LKB1-proficient HEK293Tcells. To investigate whether
LKB1 and SIK1 might exert a direct suppressive effect on
HTLV-1 proviral transcription and replication, we trans-
fected HeLa and HEK293T cells with an HTLV-1 infectious
clone termed pX1MT [36]. pX1MT has previously been
shown to direct the expression of viral antigens, produce
infectious virus, and immortalize primary T cells [36,37]. At
72 hr post-transfection, proviral transcription was moni-
tored by real-time RT-PCR assay. Consistently, the expres-
sion of proviral transcripts for Tax, Gag, Pol, Env and XII
from pX1MT was significantly repressed in the presence of
LKB1-WT and to a lesser extent by the SIK1-T182D
Figure 5 Requirement of SIKs, CRTCs and CREB in LKB1-mediated suppression of HTLV-1 LTR. (A) Compromising CRTC1 and CREB
dampened LTR activity in LKB1-depleted cells. LKB1-depleted HEK293T cells, as shown in Figure 3A, were cotransfected with plasmids pLTR-Luc,
pSV-RLuc, pIEX, pM1-CRTC1 and pA-CREB. * and #, the difference between the two groups is statistically significant by two tailed Student’s t test
(p = 0.020 and p = 0.0014). (B) Verification of AMPK knockdown in HeLa cells. RT-qPCR was performed to analyze AMPK and GAPDH transcripts.
The difference between bars 1 and 3 or 2 and 4 is statistically significant (p = 0.00036 or 0.0018). (C) Verification of SIK knockdown in HeLa cells.
p values were obtained for selected bars (1 and 4: 0.00046; 2 and 5: 0.0046; 3 and 6: 0.00011). (D) Endogenous SIKs in HeLa cells are required for
LKB1-mediated LTR suppression. AMPKs and SIKs were targeted by independent siRNAs at a concentration of 100 nM. siGFP was used as a
negative control. After 36 hrs of knockdown, plasmids pLTR-Luc, pSV-RLuc, pIEX and pCMV-Tag2-LKB1-WT were cotransfected into cells. Cells
were harvested 36 hrs after the second transfection. Statistically significant differences exist between group 3 and each of groups 5–11 (p values:
0.041, 0.00042, 0.0057, 0.00028, 0.00021, 0.0018 and 0.0017), whereas the difference between groups 3 and 4 was insignificant (p = 0.735).
(E) Phosphorylated CRTC1 is required for LTR suppression. HeLa cells were transfected with pLTR-Luc reporter (100 ng), a fixed amount of
Tag2-SIK2-T175D (100 ng) or Tag2-SIK3-T163D (100 ng), and escalating amounts of CRTC1 plasmid (18, 37 and 75 ng). Cells were harvested 36 hrs
after transfection. The difference between groups 16 and 20 or 16 and 24 is statistically significant (p = 0.00054 or 0.00038).
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LKB1-D194A or the SIK1-K56M dominant inactive mutant
did not affect the expression of proviral transcripts
(Figures 6A and 6B). This indicated that the kinase activity
of both LKB1 and SIK1 is critical for repression of proviral
transcription.
On the other hand, the amounts of proviral transcripts
were also examined in LKB1-depleted HEK293T cells.
The effectiveness of LKB1 depletion by two independent
siRNAs was verified (Figure 6C, lanes 3 and 4 compared to
1 and 2). Consistent with aforementioned results (Figure 3),
knockdown of endogenous LKB1 in infected cells aug-
mented proviral transcription (Figures 6D and 6E), indicat-
ing a physiological suppressive role of LKB1 on HTLV-1
gene expression during viral infection.
While pX1MT-transfected cells provide a model for
acute HTLV-1 infection, HTLV-1-transformed T cells
are physiologically more relevant to chronic infection. We
found that LKB1 and SIK1/2/3 were expressed in HTLV-1-
transformed MT2, MT4 and C8166 cells (Figures 7A).
Although it was technically more challenging to trans-
fect siRNAs into MT4 and C8166 cells, we managed to
suppress the expression of endogenous LKB1 in these cells
with siLKB1-1 using a new transfection reagent (Figures 7B
and 7C). We further showed a significant enhancement
of Tax expression in LKB1-compromised MT4 and C8166
cells (Figures 7B-7E). As such, a 2.4- to 10.4-fold eleva-
tion of the relative levels of Tax transcript or protein
was observed when LKB1 expression was knocked down
(Figures 7B-7E). Collectively, our results supported a phys-
iological role of LKB1 in suppressing proviral transcription
in HTLV-1-infected cells.
Anti-HTLV-1 and antiproliferative effect of metformin
Our observations that LKB1 and SIKs negatively regulate
HTLV-1 transcription provide the foundation for rational
design and development of molecularly targeted anti-
HTLV-1 and anti-ATL drugs. As the first step towards this
end, we tested a pharmaceutical activator of LKB1 and
SIKs, metformin. As one of the most commonly used
antidiabetic drugs, metformin is known to exert its thera-
peutic effects by activating LKB1 and AMPKs [38,39].
We first verified the activation of LKB1-SIKs axis in cul-
tured cells treated with metformin. Indeed, incubation of
HEK293T cells with increasing amounts of metformin
caused a progressive increase in the levels of both
phospho-LKB1-S428 and phospho-SIK1-T182 (Figure 8A,
lane 3 and 4 compared to 2), indicative of the activation of
LKB1 and SIKs by metformin. Ectopic expression of LKB1
alone also enhanced SIK1-T182 phosphorylation (Figure 8A,
lane 1 compared to 2).
Treatment of three lines of HTLV-1-transformed cells
(MT2, MT4 and C8166) with increasing doses of metfor-
min resulted in a progressive reduction in the levels of Taxprotein (Figure 8B, lanes 2–4 compared to 1, lanes 6–8
compared to 5, and lanes 10–12 compared to 9). Likewise,
treatment of MT4 cells with 2-deoxyglucose (2-DG) also
reduced steady-state protein levels of Tax (Figure 8C,
lanes 3–5 compared to 1). Previously, 2-DG has been
shown to stimulate phosphorylation of LKB1 at both S307
and S428, leading to enhanced activity [39]. To verify
that the reduction in Tax expression was attributed to
transcriptional repression of LTR in the proviral genome
of HTLV-1-transformed cells, we also measured the
amounts of Tax transcript. Treatment with three different
doses of metformin diminished the levels of Tax mRNA in
MT2, MT4 and C8166 cells at two different time points
(Figures 8D-8G). Furthermore, measurement of reverse
transcriptase activity associated with live HTLV-1 virus
indicated that treatment with metformin suppressed in a
dose-dependent manner the production of cell-free HTLV-
1 virions released to the culture supernatant of MT2 cells
(Figure 8H). These data consistently supported a repressive
effect of metformin on HTLV-1 transcription and viral
protein expression.
Because HTLV-1 and its Tax protein are thought to
drive T cell proliferation and transformation [1,12], we
believed it would be of interest to see whether and how
inhibition of HTLV-1 transcription and Tax expression by
metformin might affect cell proliferation. Indeed, treat-
ment of HTLV-1 transformed MT4, MT2 and C8166 cells
with metformin effectively reduced cell proliferation in a
dose- and time-dependent manner (Figures 8I and 8J). In
contrast, the proliferation of HTLV-1-negative Jurkat cells
was not significantly affected. Importantly, depletion of
LKB1 in MT2 cells by siLKB1-1 reversed the growth sup-
pressive effect of metformin (Figure 8K), implicating that
metformin suppresses proliferation of HTLV-1-positive
cells through activation of LKB1.Discussion
In this study we provided the first evidence that LKB1
and SIKs negatively regulate HTLV-1 gene expression.
We first demonstrated a kinase-dependent suppression
of Tax-mediated activation of HTLV-1 LTR by LKB1 and
SIKs (Figures 1,2,3,4). We next determined the compo-
nents of the LKB1-initiated signaling cascade which amp-
lifies and transmits the inhibitory signal to CREB and Tax
plausibly through sequential phosphorylation of SIKs and
CRTCs (Figure 5). We also documented LKB1-mediated
inhibition of proviral gene transcription in HTLV-1
-infected cells (Figures 6 and 7). Finally, we demonstrated
the anti-HTLV-1 and antiproliferative activity of metfor-
min, a small-molecule agonist of LKB1 and SIKs (Figure 8).
Our finding of a previously unrecognized link of LKB1
and SIKs to transcriptional control of HTLV-1 reveals an-
other level of regulation relevant to HTLV-1 pathogenesis
Figure 6 Modulation of LKB1 and SIK1 influences HTLV-1 proviral transcription. (A and B) LKB1 and SIK1 suppressed proviral transcription
in a kinase-dependent manner. HeLa cells were co-transfected with pX1MT plus pCMV-Tag2 (vector), LKB1 (WT/D194A) or SIK1 (T182D/K56M).
Cells were harvested 72 hrs after transfection. Total RNA was extracted and cDNA was synthesized. Semi-quantitative and quantitative RT-PCR was
performed to analyze the relative levels of proviral Tax, Gag, Pol, Env, XII and GAPDH transcripts. The differences between bars 1 and 2, 1 and 4, 6
and 7, 6 and 9, 11 and 12, 11 and 14, 16 and 17, 16 and 19, 21 and 22, as well as 21 and 24 are statistically significant by two tailed Student’s t
test (p values: 0.000014, 0.0026, 0.0036, 0.00061, 0.0033, 0.0075, 0.00031, 0.0078, 0.0000023 and 0.00013). (C) Verification of LKB1 knockdown in
HEK293T cells. Cells were transfected with siRNAs against LKB1 or non-specific control siRNA (siNC) for 72 hrs. Cell lysates were analyzed by
Western blotting. (D and E) Depletion of endogenous LKB1 potentiated HTLV-1 proviral transcription in infected cells. After 36 hrs of LKB1
knockdown, cells were co-transfected with pX1MT for 36 hrs. Cells were harvested and total RNA was extracted for cDNA synthesis. Semi-quantitative
and quantitative RT-PCR was performed to analyze the expression of proviral Tax, Pol and Env transcripts. Statistically significant differences exist
between bars 1 and 2, 1 and 3, 4 and 5, 4 and 6, 7 and 8, 7 and 9, 10 and 11, 10 and 12, 13 and 14, 13 and 15, 16 and 17, as well as 16 and 18 (p values:
0.000014, 0.00000078, 0.00000021, 0.0000012, 0.0000085, 0.00000014, 0.00000019, 0.00000060, 0.0000025, 0.000000071, 0.000035 and 0.000013).
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HTLV-1 transcription and replication are critical to the
initiation and progression of ATL. Although the exact
mechanism of Tax function remains incompletely under-
stood [1], transcriptional activation from the HTLV-1 LTR
bears similarities with that driven by cellular CREs. Several
lines of evidence in the literature supported the role of
LKB1-SIK cascade in the regulation of CRTC activity at
cellular CREs. First, LKB1 is a master kinase which acti-
vates more than 14 AMPK-related kinases, three of which
have been implicated in the regulation of CREB signaling
[16]. Second, SIK1 is known to inhibit cAMP-induced
transcription [40]. Third, CRTCs interact with CREB and
augment CREB activity [41,42]. Finally, SIKs phosphory-
late CRTCs and induce their cytoplasmic retention [35,43].
In line with this model, enforced expression of LKB1 in
LKB1-deficient HeLa cells led to phosphorylation and acti-
vation of SIKs, restoring nucleocytoplasmic shuttling ofCRTCs [27]. Some of these findings on cellular CREs are
relevant to HTLV-1 LTR.
LKB1 is a highly efficient suppressor of HTLV-1 tran-
scription. Expression of LKB1 in HeLa cells led to an al-
most complete shut-down of the activity of Tax (Figure 1).
In this setting Tax expression driven by a CMV promoter
was unaffected by LKB1. Thus, the observed inhibition
of LTR activity by LKB1 was not mediated by an indirect
effect on Tax. Our findings presented in Figures 2, 3 and 5
are consistent with the notion that LKB1 phosphorylates
and activates SIKs, which in turn phosphorylates and inac-
tivates CRTCs, leading to the inhibition of CREB and Tax.
Additional loss-of-function and gain-of-function experi-
ments in HTLV-1-infected T cells will provide further sup-
port to this model. The S167 phosphorylation-independent
mechanism through which SIK2 and SIK3 regulate CRTC1
(Figure 5E) also merits further investigations. Because
CREB is required for the transcription of other oncogenic
viruses such as hepatitis B virus [44,45], it will be of interest
Figure 7 Knockdown of LKB1 enhances Tax expression in HTLV-1-transformed cells. (A) Expression of LKB1 and SIKs in HTLV-1-transformed
cells. RT-qPCR was performed to analyze LKB1, SIK1/2/3 and GAPDH transcripts. Quantitation of mRNA expression was achieved by comparative
Ct method. The differences between bars 5 and 6, 5 and 7, 5 and 8, as well as 13 and 16 are statistically significant by two tailed Student’s t test
(p values: 0.000011, 0.000082, 0.000000076 and 0.00040). (B and C) Verification of LKB1 knockdown by siRNA. siLKB-1 was transfected into MT4 and
C8166 cells using TransIT-Jurkat transfection reagent (Mirus). Endogenous proteins were analyzed by Western blotting at 48 hrs post-transfection using
mouse anti-LKB1, mouse anti-Tax and mouse α-tubulin (α-tub). Relative amounts of LKB1 or Tax normalized to α-tubulin were determined by
densitometry and are indicated at the bottom of the panels. (D and E) Knockdown of endogenous LKB1 enhanced Tax expression in HTLV-1
-transformed cells. siLKB1-1 at a concentration of 100 nM was used to deplete endogenous LKB1 in MT4 and C8166 cells. Cells were harvested and
total RNA was extracted for cDNA synthesis. Quantitative PCR was performed to analyze Tax and GAPDH transcripts. ***, the difference between the
two groups is statistically significant by two tailed Student’s t test (p = 0.00005, MT4; p = 0.001, C8166).
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scription as well.
In addition to LKB1, SIKs were also found to suppress
HTLV-1 transcription in this study. To our surprise,
AMPKs, which are also activated by LKB1 and can regu-
late CRTC activity in other systems [28], were not in-
volved in Tax activation of LTR (Figures 2A and 5D).
This implies that Tax recruitment of LKB1 substrates
has specificity. The inhibition of LTR activation was
apparently more prominent when SIK1 + SIK2, SIK1 +
SIK3 or SIK1 + SIK2 + SIK3 were expressed in combi-
nation (Figure 2E). Consistently, LTR activity was most
robust when all three SIKs were compromised (Figure 5D).
This functional redundancy and cooperativity of SIKs
might be relevant to the regulation of HTLV-1 transcrip-
tion in different cell types and different stages of viral in-
fection. In this regard, it will be of interest to further
investigate the synergistic actions of SIK1, SIK2 and SIK3
in mouse models.
The inactivation of additional tumor suppressors such
as p53 might play a role in ATL development and progres-
sion [46]. One previous study suggested chromosomal
rearrangements at 19p13.3, which harbors the LKB1tumor suppressor, in some ATL cells [21]. Although LKB1
and all three SIKs were expressed in MT2, MT4 and
C8166 cells (Figure 7), it will still be of great interest to see
whether genetic and epigenetic inactivation of LKB1 and
SIKs might occur in ATL cells and help to further propa-
gate Tax-initiated transformation. Whereas Tax activation
of NF-κB is thought to be important in leukemogenesis,
CREB signaling is also required for sustained transfor-
mation [12]. Leukemogenesis is driven by multiple forces
including the targets of CREB, HTLV-1 transcription and
Tax [1,12]. In this sense, inactivation of LKB1 and SIKs
might promote ATL development through uncontrolled
activation of CREB and the HTLV-1 LTR.
Preferential association of Tax with active LKB1 and
SIKs (Figure 4) is consistent with the notion that Tax or-
chestrates HTLV-1 transcription by recruiting both acti-
vators and inhibitors. Tax plays a central role in HTLV-1
transcription and it interacts physically with various cel-
lular regulators of the LTR including CRTCs and CREB
[7]. The recruitment of active LKB1 and SIKs by Tax
plausibly adapts them to CRTCs. This might constitute a
negative feedback circuit that controls the magnitude
and duration of LTR activation. Plausibly, the expression
Figure 8 Metformin activates LKB1-SIK axis and suppresses HTLV-1 proviral gene expression and cell proliferation. (A) Treatment with
metformin triggered phosphorylation of LKB1 and SIK1. Confluent HEK293T cells were exposed to metformin (0.5 and 1 mM for 30 min) as
described [39]. (B) Diminution of Tax protein in HTLV-1-transformed cells treated with metformin. Cells were treated with metformin (5, 10 and 20 mM)
for 24 hrs. (C) Effect of metformin and 2-DG on Tax expression. MT4 cells were treated with metformin (10 mM) or 2-DG (50, 100, 150 mM) for 24 hrs.
(D and E) Time course of metformin-induced downregulation of Tax mRNA production. Cells were treated with metformin (1 mM) for 24 and 36 hrs.
Quantitative PCR was performed to analyze Tax and GAPDH transcripts. Relative Tax mRNA expression in mock-treated cells was taken as 1.
*, p = 0.013. **, p = 0.004 (MT4 and MT2). ***, p = 0.00006. (F and G) Dose dependence of metformin-induced downregulation of Tax mRNA production.
Cells were treated with metformin (2 and 5 mM) for 24 hrs. ***, p = 0.002 and p = 0.0003 for MT4; p = 0.0001 and p = 0.00003 for C8166. (H) Metformin
inhibited HTLV-1 virion production. Cells were treated with metformin (5, 10 or 20 mM). Overnight production of cell-free HTLV-1 virions was assessed by
measuring reverse transcriptase activity recovered from live HTLV-1 virus in the culture supernatant with a colorimetric assay kit (Roche). *, p = 0.0059.
(I and J) Metformin inhibited proliferation of HTLV-1-transformed cells. Cell viability was measured by MTT method. (K) Metformin-mediated growth
inhibition is LKB1-dependent. LKB1-depleted MT2 cells were treated with metformin (20 mM) for 24 hrs. **, p = 0.005, left; p = 0.008, right.
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would govern LTR activation in different biological
contexts.
The strongest suppression of HTLV-1 LTR by LKB1
and SIKs was observed in transfected HeLa and
HEK293T cells (Figures 1,2,3). Not to our surprise, the
suppressive effects were moderate in T-cell lines,plausibly due to low transfection efficiency (Figures 6,7,8).
Nevertheless, our gain-of-function and loss-of-function
studies performed in pX1MT-transfected and HTLV-1-
transformed cells (Figures 6 and 7) consistently supported
the notion that LKB1 and SIKs are physiological regula-
tors of HTLV-1 transcription. Hence, pharmaceutical acti-
vation of LKB1 and SIKs in HTLV-1-infected cells would
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transformation. Although HTLV-1 leukemogenesis is a
slow process, high proviral loads are a major risk fac-
tor for disease progression [3]. Thus, reducing pro-
viral loads with small-molecule agonists of LKB1 and
SIKs, such as metformin, might reduce the risk for
development of ATL.
Indeed, we demonstrated an anti-HTLV-1 and an LKB1-
dependent anti-proliferative activity of metformin in
HTLV-1-transformed cells (Figure 8). Further investigations
are required to determine the in vivo relevance of these
findings. Particularly, it will be intriguing to see whether
metformin would exhibit anti-HTLV-1 and antiproliferative
activity in an animal model. Metformin is one of the most
commonly used anti-diabetic drugs. Long-term use of met-
formin is both well tolerated and highly effective in the acti-
vation of LKB1 and downstream kinases [47]. Thus,
metformin might be useful not only in patients with ATL,
but also in HTLV-1 carriers who are at risk for develop-
ment of ATL. In this regard, epidemiological studies would
be performed to assess retrospectively whether the use of
metformin in diabetic HTLV-1 carriers might have reduced
the risk for development of HTLV-1-associated diseases.
Conclusion
Our study defines a negative regulatory role of LKB1 and
SIKs in HTLV-1 transcription, which operates through
CRTCs and CREB. Our work also provides the proof-of-
concept for the utility of metformin, a small-molecule
agonist of LKB1 and SIKs, in anti-HTLV-1 and anti-ATL
therapy.
Methods
Cell culture and transfection
HeLa and HEK293T cells were cultured in Dulbecco modi-
fied Eagle medium supplemented with 10% fetal calf serum,
2 mM l-glutamine and 1% penicillin/streptomycin at 37°C
in a humidified atmosphere of 5% CO2. Jurkat and other
HTLV-1-transformed T cells (MT2, MT4 and C8166) were
maintained in RPMI1640 medium supplemented with fetal
calf serum and penicillin/streptomycin.
HeLa and HEK293T cells were transfected using Gene-
Juice transfection reagent (Novagen). Jurkat and other
HTLV-1-transformed cells were transfected using Lipo-
fectamine 2000 (Invitrogen).
Plasmids and antibodies
Reporter plasmid pLTR-Luc and expression plasmids
for Tax, A-CREB, CRTC1, CRTC1-S167A, CRTC1-M1,
SIK2, SIK3, AMPK and AMPK-T172D have been detailed
elsewhere [7,17,27,48]. Tax expression plasmid pIEX is
driven by a cytomegalovirus (CMV) promoter [49]. The
pCAG-Tax-V5 expression plasmid was derived from pIEX.
LKB1 cDNA in the pCMV-Tag2-LKB1 expression plasmidwas derived from EST clone IRAUp969C0840D. The
pCMV-Tag2-SIK1 plasmid was derived from pWZL-Neo-
Myr-Flag-SNF1LK provided by Jean Zhao [50]. pCMV-
Tag2-SIK2 and pCMV-Tag2-SIK3 were derived from
pEBG-SIK2 and pEBG-SIK3, respectively [27].
Mutants for LKB1, AMPKα2 and SIKs were generated
by Quikchange Site Directed Mutagenesis kit XL (Agilent).
DNA sequencing confirmed that all mutations were suc-
cessfully introduced. The HTLV-1 infectious clone pX1MT
has been described previously [36]. Metformin, 2-deoxy-D-
glucose (2-DG), rabbit anti-V5, mouse anti-Flag, mouse
anti-β-actin and mouse anti-α-tubulin were obtained from
Sigma-Aldrich. Mouse anti-V5 was from Invitrogen.
Mouse anti-LKB1 (Ley37D/G6), anti-GST and anti-GFP
were from Santa Cruz Biotechnology. Rabbit antibodies
against phospho-LKB1-S428 and phospho-acetyl coenzyme
A carboxylase-S79 (p-ACC) were from Cell Signaling and
Millipore, respectively. Mouse anti-Tax and rabbit anti-
phospho-SIK1-T182 have been described [27].
Reporter assays and protein analysis
The dual luciferase assay and protein analysis were per-
formed as described previously [7,17]. Cells were
harvested 36 or 48 hrs after transfection. Transfection effi-
ciencies were normalized to pSV-RLuc (Promega). Three
independent experiments were performed and error bars
indicate standard deviations (SD). Differences between in-
dicated groups were statistically analyzed by two tailed
Student’s t test.
Protein affinity precipitation
HEK293T cells grown in 100-mm petri dish were
harvested into 1 ml of immunoprecipitation buffer
(20 mM Tris–HCl, pH 7.5, 100 mM NaCl, 0.5 mM
EDTA, 0.5% NP-40, 1 mM dithiothreitol, 20 mM
β-glycerophosphate, 1 mM sodium vanadate, and 1 mM
phenylmethylsulfonyl fluoride). Flag-LKB1/SIK1, V5-Tax
or GST-SIK2/SIK3 protein was precipitated from the
cleared lysate after a 2-hr incubation at 4°C with mouse
anti-Flag (M2, Sigma), mouse anti-V5 (Invitrogen) or gluta-
thione Sepharose 4B (GE Healthcare). Immunoprecipitates
were collected with protein G agarose (Invitrogen). Protein
complexes were washed three times with immunoprecipita-
tion buffer and subsequently resuspended in sample buffer
(50 mM Tris-Cl, 2% sodium dodecyl sulfate, 5% glycerol,
1% β-mercaptoethanol, and 0.002% bromophenol blue). For
immunoprecipitation of endogenous Tax, HTLV-1 trans-
formed cells (MT2, MT4 and C8166) were harvested in
1 ml of immunoprecipitation buffer. Cleared lysate was
then incubated with mouse anti-Tax.
RNA interference (RNAi)
HeLa and HEK293T cells were transfected with 100 nM
siRNA using Lipofectamine 2000 (Invitrogen). MT2, MT4
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transfection reagent (Mirus). RNAi experiments were
performed as described [51]. siRNA sequences are listed
in Additional file 2: Table S1.
Real-time RT-PCR
Real-time RT-PCR was performed as previously described
[52,53]. Primer sequences are listed in Addditional file 2
Table S1. Briefly, total RNA was extracted using RNAiso
Plus reagent (TaKaRa) and cDNA was synthesized by
Transcriptor First Strand cDNA Synthesis Kit (Roche)
using random hexamer primers. RNA expression was
quantified by real-time PCR using SYBRW Premix Ex
Taq™ reagent (TaKaRa) and StepOne™ real-time PCR sys-
tem (Applied Biosystems). The normalized value in each
sample was calculated as the relative quantity of mRNA
divided by the relative quantity of GADPH transcript.
Quantitation of target mRNA expression was achieved
with the comparative Ct method. Relative expression level
of target mRNA was calculated from 2-ΔCt.
Cell proliferation assay
Cell proliferation was assayed by the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl-tetrazolium (MTT) method
as described [54]. Briefly, 5 × 104 cells treated with
10 μl of MTT solution (5 mg/ml) were measured by a
microplate reader (Spectra Max 340, Molecular De-
vices) at a reference wavelength of 550 nm. Cell viabil-
ity was calculated as a percentage of the control. In
dose–response experiments, cells were treated with 10,
20, 30 and 50 mM metformin for 24 hrs. In time-
course analysis, cells were treated with 30 mM metfor-
min for the indicated durations.
Reverse transcriptase assay
MT-2 cells were seeded at 1 × 106/ml and cultured
overnight in the presence of escalating concentrations
of metformin (5, 10 or 20 mM). Supernatants were col-
lected and ultracentrifuged for 2 hrs at 200,000 × g.
Supernatant from cultured Jurkat cells was used as a
negative control. Reverse transcriptase activity was
measured using a colorimetric method by the use of a
reagent kit from Roche.
In vitro LKB1 activity assay
His-Tax, LKB1 trimeric complex and GST-AMPKα2
(1–312) were bacterially expressed and a kinase assay
was performed with purified recombinant proteins as
described [48]. Briefly, GST-AMPKα2 (1–312) (5 μg)
was incubated with increasing amounts of His-Tax (1, 2
or 4 μg) in AMPK kinase buffer (50 mM HEPES and
0.02% BRIJ35, pH7.0) in the presence or absence of
LKB1 trimeric complex (1.5 μg). The reaction wasperformed in the presence of 20 μM ATP at 30°C for
15 min. Proteins were resolved by SDS-PAGE and
detected by Western blotting.
Additional files
Additional file 1: Figure S1. LKB1 kinase activity was unaffected by Tax
in vitro. GST-AMPKα2 (1–312) (5 μg) was incubated with increasing
amounts of His-Tax (1, 2 and 4 μg) in the presence or absence of LKB1
trimeric complex (1.5 μg) in an in vitro kinase assay. Proteins were
resolved by SDS-PAGE and detected by Western blotting.
Additional file 2: Table S1. Nucleotide sequences of RT-PCR primers
and siRNAs.
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